SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is trending sharply lower following the government's proposal for an unexpectedly minimal increase in 2027 Medicare Advantage payment rates, sparking broad concerns across the health insurance sector. While many view the significant sell-off as an overreaction and a long-term buying opportunity due to strong fundamentals, others anticipate further declines, highlighting policy risk and the ongoing political scrutiny on healthcare profitability.

Richtech Robotics, Inc. engages in the development of robotics and artificial intelligence. The firm designs, manufactures, and sells robots to restaurants, hotels, senior living centers, casinos, factories, and movie theaters. Its robots perform a variety of services including restaurant running and bussing, hotel room service delivery, floor scrubbing and vacuuming, and beverage and food preparation. The company was founded by Zhen Wu Huang and Zhen Qiang Huang on July 19, 2016 and is headquartered in Las Vegas, NV.

Richtech Robotics Inc. - Ordinary Shares - Class B

Richtech Robotics Inc.

Richtech Robotics ($RR) is capturing significant attention following its collaboration with Microsoft's AI Co-Innovation Labs to integrate advanced agentic AI into its ADAM robot, highlighting a pivotal development in the robotics sector. The community is actively discussing the potential for a sustained rally and short squeeze, though some express skepticism about the full impact of the partnership on the company's valuation.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is trending amid growing community excitement fueled by recent institutional interest, including a notable ownership stake by Bank of Nova Scotia and increased ETF allocations. Investors are eagerly anticipating significant "contract news" for its high-performance computing (HPC) data centers, hoping to see the company re-rated as a pure-play AI infrastructure provider rather than solely a Bitcoin miner. This anticipation is driving discussions around its potential to lead in the energy-intensive computing sector.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is a hot topic as its earnings report approaches, with the early release date fueling strong community speculation about a significant new deal, potentially with a hyperscaler like Amazon or AWS. Investors are optimistic, anticipating IREN's strategic pivot to AI infrastructure will unlock substantial value given the high demand for GPU-centric data capacity. Many believe the company is well-positioned in the rapidly expanding AI cloud sector, despite discussions around its historical correlation to Bitcoin price movements.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

SPDR Gold Shares (GLD) is trending due to its recent surge to new all-time highs, fueled by increasing geopolitical instability, a depreciating US Dollar, and heightened central bank demand for physical gold. The community is sharply divided, debating whether this parabolic move is a legitimate hedge against fiat currency debasement or a speculative 'mania' ripe for a significant pullback.

GRI Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for inflammatory, fibrotic, and autoimmune diseases. It focuses on its lead program, GRI-0621, an inhibitor of type 1 invariant Natural Killer T (iNKT) cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The company was founded by Vipin Kumar Chaturvedi in May 2009 and is headquartered in La Jolla, CA.

GRI Bio Inc

GRI Bio Inc. is actively trending following its recent 1-for-28 reverse stock split, which has created an exceptionally low float of approximately 500k shares. This development, coupled with recently announced positive Phase 2a clinical data and secured funding, is driving intense community discussion: many anticipate a significant short squeeze comparing it to prior low-float runners, while others express deep skepticism citing the company's history of frequent dilutions and management's perceived lack of trustworthiness.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

iShares Silver Trust (SLV) is a major talking point as strong physical demand from global governments and industries like AI and EVs drives its significant rally, exacerbated by a weaker dollar. Community members are fiercely divided, with bulls anticipating a historic short squeeze due to supply deficits and alleged manipulation, while bears warn of an unsustainable bubble poised for a sharp correction.

Cipher Mining, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Mining Inc

Cipher Mining is generating significant buzz following analyst endorsements recognizing its AI/HPC colocation strategy and major contracts with hyperscalers. The community highlights strong institutional interest and buying pressure, viewing the stock as increasingly driven by its data center expansion rather than solely by Bitcoin's fluctuations, with many anticipating substantial upside.

Flora Growth Corp. engages in the production of organic cannabis and pharmaceutical-grade medical products. It operates through the following segments: House of Brands and Commercial and Wholesale. The House of Brands segment includes multiple categories including food and beverage, nutraceuticals, cannabis accessories and technology, personal care and wellness. The Commercial and Wholesale segment includes distribution of pharmaceutical products to international markets. The company was founded on March 13, 2019 and is headquartered in Fort Lauderdale, FL.

Flora Growth Corp

Flora Growth Corp. is generating significant buzz as it rebrands to ZeroStack Corp., signaling a strategic pivot towards an AI-focused asset management company with a substantial treasury of 0G decentralized AI tokens. The community is actively discussing the company's ultra-low float and perceived undervaluation, driven by the value of its crypto assets relative to its market capitalization. This has fueled widespread speculation for a potential explosive move, with many closely watching the recently approved forward stock split as a sign of management's confidence in future growth.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is trending as investors assess its strategic role in the TikTok deal, which many bulls hail as a significant long-term boost for cloud revenue and AI infrastructure. This optimistic outlook is tempered by ongoing community discussion and analyst concerns regarding the company's substantial capital expenditures and increasing debt for AI buildout, leading to sharp divergence in investor sentiment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

 ETFs to Buy Post JNJ's Q4 Earnings Surprise & Bullish Cash Flow View

JNJ beat Q4 earnings and sales estimates and sees 2026 free cash flow rising to $21B, making healthcare ETFs a safer way to play its momentum.

Winners & Losers: The ETF Playbook to Glide Trump's Great Healthcare Plan

Trump's Great Healthcare Plan redraws healthcare winners and losers - here's how ETFs like IHE could benefit as middlemen face pressure.

<ul class="summary-bullets"><li>The move is a major step toward FDA approval of NRX-100, its investigational drug.</li><li>Currently, no FDA-approved medications exist specifically to treat suicidal thoughts, with electroshock therapy remaining the only sanctioned option.</li><li>Earlier, Osmind presented data from a 20,000-patient subset at the 2024 American Society of Clinical Psychopharmacology meeting.</li></ul>NRx Pharmaceuticals, Inc. (NRXP) on Wednesday announced that it has licensed Real World Evidence (RWE) from more than 70,000 U.S. patients who received either intravenous ketamine or nasal S-ketamine as part of their treatment.The move is a major step toward FDA approval of its investigational drug, NRX-100 (preservative-free ketamine), aimed at treating suicidal ideation in patients with depression and suicidal tendencies.&nbsp;<h2 class="st-heading-2">Collaboration With Osmind</h2>The RWE data comes from Osmind, a neuropsychiatry technology platform used across U.S. clinics, providing detailed, regulatory-grade patient records. This joint effort allows NRx to submit a comprehensive dataset to the FDA in support of Accelerated Approval for NRX-100 under its Fast Track Designation.&nbsp;The approach could mark a breakthrough, as currently no FDA-approved medications exist specifically to treat suicidal thoughts, with electroshock therapy remaining the only sanctioned option.Following the update,&nbsp;<a href="https://stocktwits.com/symbol/NRXP">NRx Pharmaceuticals' stock&nbsp;</a>traded over 21% higher in Wednesday’s premarket.&nbsp;On Stocktwits, retail sentiment around the stock jumped to ‘bullish’ territory from ‘bearish’ the previous day. Message volume shifted to ‘high’ from ‘normal’ levels in 24 hours.&nbsp;<h2 class="st-heading-2">Preliminary Findings And Expectations</h2>Earlier, Osmind presented data from a 20,000-patient subset at the 2024 American Society of Clinical Psychopharmacology meeting. Results suggested rapid improvement in depression and suicidal ideation with intravenous ketamine.&nbsp;NRx anticipates that analysis of the full 70,000-patient dataset will provide even stronger evidence to support the FDA submission.<blockquote>“An American commits suicide every 11 minutes and ketamine has become widely used off label as a drug that has been seen to reduce suicidal ideation in clinical trials.”-Jonathan Javitt, Chairman and CEO, NRx Pharmaceuticals</blockquote>NRXP stock has declined by over 58% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-nrxp-stock-surge-pre-market-today/cmULXc2R4eL">Why Did NRXP Stock Surge 21% Pre-Market Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a hand holding a medical syringe seen displayed in front of the NRx Pharmaceuticals logo.

Why Did NRXP Stock Surge 21% Pre-Market Today?

The company is using a large US real-world evidence dataset to support its accelerated FDA approval for its ketamine-based drug.

Equity

The company is using a large US real-world evidence dataset to support its accelerated FDA approval for its ketamine-based drug.


<ul class="summary-bullets"><li>The co-innovation lab will use Nvidia’s new Vera Rubin chips and be built on its BioNeMo platform, while leveraging Lilly’s pharmaceutical expertise.</li><li>Apart from drug discovery, the collaboration will also explore AI’s use in clinical development, manufacturing, and commercial operations that can integrate multimodal models, agentic AI, robotics, and digital twins.</li><li>The lab is expected to begin operations early this year.</li></ul>Nvidia Corp. (NVDA) and Eli Lilly (LLY) announced on Monday that the two companies will jointly invest $1 billion over five years to build a new joint research lab in the San Francisco Bay area.The co-innovation lab will leverage Nvidia’s new Vera Rubin chips and be built on the company’s BioNeMo platform, while leveraging Eli Lilly’s pharmaceutical expertise to accelerate medicine development, the companies said.The lab will expand on the U.S. pharma giant’s previously-announced artificial intelligence (AI) supercomputer and will use Nvidia’s next-generation architectures.Apart from drug discovery, the collaboration will also seek to explore ways to use AI in clinical development, manufacturing, and commercial operations that can integrate multimodal models, agentic AI, robotics, and digital twins. The lab is expected to begin operations early this year.<a href="https://stocktwits.com/symbol/NVDA">Shares of NVDA</a> were up 0.09% at the time of writing, while <a href="https://stocktwits.com/symbol/LLY">shares of LLY</a> were up 0.79% at the same time.<h2 class="st-heading-2">Eli Lilly’s AI Push</h2>Nvidia and Lilly’s joint announcement comes at the start of the 44th Annual JPMorgan Healthcare Conference in San Francisco and follows the drugmaker’s announcement from October 2025 of launching a supercomputer, also leveraging 1,000 Nvidia Blackwell Ultra GPUs.The supercomputer would power an AI factory or a specialized computing infrastructure to manage the entire AI lifecycle from data input and training to fine-tuning and high-volume inference, the company had announced then.The AI factory will now be used to train large biomedical foundation and frontier models for identifying, optimizing and validating new molecules with exceptional speed and accuracy while also supporting advanced applications in manufacturing, medical imaging and scientific AI agents.“For nearly 150 years, we’ve been working to bring life-changing medicines to patients,” David A. Ricks, chair and CEO of Eli Lilly said. “Combining our volume of data and scientific knowledge with NVIDIA’s computational power and model-building expertise could reinvent drug discovery as we know it.”Lilly’s competitor Novo Nordisk (NVO) has also been making a significant push into AI, partnering with major tech firms including Nvidia, Microsoft, and AWS across its value chain.<h2 class="st-heading-2">Nvidia’s Healthcare Market Exploration</h2>Nvidia, the most valuable corporation in the world, has been exploring healthcare and pharmaceuticals as new markets for its AI chips.Apart from the deal with Lilly, the semiconductor company also announced a collaboration with research company <a href="https://stocktwits.com/symbol/TMO">Thermo Fisher Scientific Inc.</a> (TMO) for manufacturing scientific instruments that are intelligent as well as autonomous labs.Nvidia’s BioNeMo and NeMo platforms are also being adopted by other firms for biotech and drug discovery to power foundation models, AI-driven molecular design, and autonomous “AI scientist” systems as well as for robotics and lab automation to introduce simulation, and physical AI technologies.“AI is transforming every industry, and its most profound impact will be in life sciences,” said Jensen Huang, Nvidia’s founder and CEO.“NVIDIA and Lilly are bringing together the best of our industries to invent a new blueprint for drug discovery — one where scientists can explore vast biological and chemical spaces in silico before a single molecule is made,” he said about the deal with Lilly.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around NVDA shares were in the ‘extremely bullish’ territory over the past 24 hours amid ‘high’ message volumes at the time of writing.Meanwhile, retail sentiment around LLY shares were ‘bullish’ at the same time with ‘high’ message volumes.Shares of NVDA climbed over 38% in the past year while LLY shares rose over 34% in the same time.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of Nvidia is displayed on a smartphone screen on November 24, 2025 in Chongqing, China.

Nvidia, Lilly Team Up For $1B Drug AI Lab

The two companies will invest the funds over five years to build a new joint research lab in the San Francisco Bay area. 

5 ETFs to Buy for January 

5 ETFs to buy in January: momentum, small caps, chips, defense and healthcare shine as markets rally early in 2026 -- IWM, MTUM, SMH, XAR and IHE.

Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?

<ul class="summary-bullets"><li>The trial had 24 patients, exceeding the original target of 20, and included a 4-week baseline.</li><li>In the Absence cohort, patients experienced a median 73.1% reduction in seizures.</li><li>The DEE cohort saw a median 63.3% decrease in major motor seizures.</li></ul>Shares of Bright Minds Biosciences Inc. (DRUG) rose over 51% on Tuesday morning, after the company announced promising topline results from its Phase 2 BREAKTHROUGH trial evaluating BMB-101.BMB-101 is a selective 5-HT2C biased agonist, in adults with drug-resistant Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE). The study met its primary goals, showing strong reductions in seizure frequency while maintaining a favorable safety profile.<h2 class="st-heading-2">Trial And Participants</h2>The trial had 24 patients, exceeding the original target of 20, and included a 4-week baseline, 4-week titration, and maintenance period consisting of&nbsp;2 weeks for the Absence cohort and 4 weeks for the DEE cohort.&nbsp;Participants were heavily pretreated, with a median of 3 anti-seizure medications in the Absence cohort and 5 in the DEE cohort, having failed multiple prior therapies.&nbsp;On Stocktwits, retail sentiment around the&nbsp;<a href="https://stocktwits.com/symbol/DRUG">stock</a> jumped to ‘extremely bullish’ from ‘bearish’ territory. Message volume improved to ‘extremely high’ from ‘low’ levels in 24 hours.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_01_06_085410_png_a041b522e5.webp" alt="DRUG’s Sentiment Meter and Message Volume as of 09:35 a.m. ET on Jan. 6, 2026 | Source: Stocktwits" width="924" height="102"><figcaption>DRUG’s Sentiment Meter and Message Volume as of 09:35 a.m. ET on Jan. 6, 2026 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">Seizure Reduction</h2>In the Absence cohort, patients experienced a median 73.1% reduction in seizures lasting more than or equal to three seconds and a 74.4% decrease in total seizure time over 24 hours.&nbsp;The DEE cohort, including patients with Lennox-Gastaut Syndrome (LGS), Dravet syndrome, and Rett syndrome, saw a median 63.3% decrease in major motor seizures. LGS patients achieved a 60.3% reduction, while other DEE participants experienced a 76.1% reduction.&nbsp;Beyond seizure control, BMB-101 increased REM sleep by 90%, from 56.2 to 106.7 minutes, without altering total sleep duration.DRUG stock has gained over 93% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-arwr-stock-surge-pre-market-today/cmxwuZ6R4TS">Why Did ARWR Stock Surge Over 15% Pre-Market Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The Technician Reads Eeg Data While Subjecting The Boy To A Variety Of Visual And Respiratory Stimuli Stroboscopy.

Why Did DRUG Stock Rocket 51% Today?

The Phase 2 BREAKTHROUGH trial met its primary goals, showing strong reductions in seizure frequency while maintaining a favorable safety profile.

<ul class="summary-bullets"><li>The interim data show that ARO-INHBE, especially when combined with tirzepatide, doubled weight loss and tripled reductions in visceral fat.</li><li>In adults with obesity, a single 400 mg dose of ARO-INHBE reduced serum Activin E by a mean of 85%, reaching a maximum reduction of 94%.</li><li>ARO-ALK7 became the first RNAi therapy to silence an adipocyte gene in humans.</li></ul>Arrowhead Pharmaceuticals Inc. (ARWR) stock jumped over 15% in Tuesday’s premarket, after it released early data from its Phase 1/2a clinical trials of its RNA interference (RNAi) therapies, ARO-INHBE and ARO-ALK7, targeting obesity.&nbsp;The preliminary results suggest these investigational treatments may reduce body fat and improve metabolic health in patients, particularly those with type 2 diabetes.<h2 class="st-heading-2">Promising Fat Reduction</h2>The interim data show that ARO-INHBE, especially when combined with tirzepatide, a GLP-1/GIP receptor co-agonist, doubled weight loss and tripled reductions in visceral fat, total fat, and liver fat compared with tirzepatide alone.The findings mark the first human evidence that targeting the Activin E/ALK7 pathway could enhance weight loss beyond that achieved by existing incretin therapies. In adults with obesity, a single 400 mg dose of ARO-INHBE reduced serum Activin E by a mean of 85%, reaching a maximum reduction of 94%.On Stocktwits, retail sentiment around Arrowhead stock jumped to ‘bullish’ from ‘bearish’ territory. Message volume shifted to ‘high’ from ‘low’ levels in 24 hours.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_01_06_081204_png_73fc92d26b.webp" alt="ARWR’s Sentiment Meter and Message Volume as of 08:00 a.m. ET on Jan. 6, 2026 | Source: Stocktwits" width="932" height="105"><figcaption>ARWR’s Sentiment Meter and Message Volume as of 08:00 a.m. ET on Jan. 6, 2026 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">Clinical Highlights</h2>ARO-INHBE monotherapy at week 16 led to a 9.9% reduction in visceral fat, a 38% drop in liver fat, and a 3.6% increase in lean muscle. Two doses at week 24 further improved visceral fat reduction to 15.6% after adjusting for placebo.&nbsp;Combined with tirzepatide, ARO-INHBE achieved roughly double the weight loss and triple the fat reduction compared to tirzepatide alone.ARO-ALK7 became the first RNAi therapy to silence an adipocyte gene in humans, reducing ALK7 mRNA in fat tissue by an average of 88% at the 200 mg dose, with a peak reduction of 94%. Early data also showed a 14.1% reduction in visceral fat after a single dose at week 8, adjusted for placebo.ARWR stock has gained over 227% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ondas-stock-draws-bullish-retail-chatter-ahead-of-key-investor-event-trader-calls-it-potential-multibagger/cmxwMoyR4T0">Ondas Stock Draws Bullish Retail Chatter Ahead Of Key Investor Event – Trader Calls It ‘Potential Multibagger’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Arrowhead Pharmaceuticals logo is seen displayed on a smartphone screen.

Why Did ARWR Stock Surge Over 15% Pre-Market Today? 

The preliminary results from Phase 1/2a clinical trials of the company’s  RNA interference (RNAi) therapies suggest the treatments may reduce body fat and improve metabolic health in patients, particularly those with type 2 diabetes.

4 Top-Ranked ETF Areas That Beat the Market in 2025

Top-ranked ETF areas that beat SPY in 2025 included semiconductors, Japan, financials and pharma. Winning ETFs were FTXL, EWJV, KBWB and IHE.



 Bet on These Top-Ranked Healthcare ETFs Before 2025 Ends

XLV and similar healthcare ETFs are gaining momentum as strength in biotech, increased AI adoption, and rising defensive demand position the sector for year-end leadership. 

IHE
iShares U.S. Pharmaceuticals ETF

Feed

News

Sentiment

Fundamentals

Info

Latest IHE News

IHEiShares U.S. Pharmaceuticals ETF